Protagonist Therapeutics (PTGX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on the stock and has a $54.00 price target.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight the potential of Protagonist Therapeutics’ rusfertide in the polycythemia vera (PV) market. The VERIFY study results were impressive, with rusfertide meeting both primary and secondary endpoints, demonstrating significant clinical response rates compared to placebo. This success suggests rusfertide’s potential as a blockbuster treatment, particularly given its ability to reduce the need for phlebotomy, a common yet undesirable treatment for PV patients.
Moreover, rusfertide’s ability to improve patient-reported outcomes, such as fatigue, sets it apart from existing treatments, enhancing its clinical profile. The safety data from the study was consistent with previous findings, alleviating concerns about adverse effects. Additionally, the potential financial benefits from milestone payments and strategic decisions regarding partnership with Takeda further support the Buy rating. The valuation of Protagonist Therapeutics, based on future revenue estimates and a high probability of success for rusfertide, reinforces the positive outlook for the company’s stock.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $58.00 price target.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTGX in relation to earlier this year.